1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 6,800 | 6,800 | 20:58 | |
| 6,700 | 6,800 | 19:21 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | CLSA: China Biotech Fundamentals Remain Solid; Top Picks BEONE MEDICINES, INNOVENT BIO and LEADS BIOLABS-B | 5 | AASTOCKS | ||
| 03.09. | M Stanley Raises LEADS BIOLABS-B TP to HKD85, Rated Equalweight | 2 | AASTOCKS | ||
| 02.09. | CLSA Raises LEADS BIOLABS-B TP to HKD116.9, LBL-024 Data to Be Released Soon | 1 | AASTOCKS | ||
| NANJING LEADS BIOLABS Aktie jetzt für 0€ handeln | |||||
| 31.08. | LEADS BIOLABS-B Interim Loss Widens to RMB222 Million; No Dividend | 1 | AASTOCKS | ||
| 31.08. | LEADS BIOLABS-B (09887): INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2026 | 2 | HKEx | ||
| 25.08. | LEADS BIOLABS CO., LTD.: Leads Biolabs' Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Phase II Clinical Study for First-Line Treatment of Esophageal Squamous Cell Carcinoma Advances to Expansion Stage | 2 | GlobeNewswire (USA) | ||
| 25.08. | LEADS BIOLABS-B Velaixin Phase II Study for Esophageal Squamous Cell Carcinoma Enters Expansion Stage | 1 | AASTOCKS | ||
| 25.08. | LEADS BIOLABS-B (09887): VOLUNTARY ANNOUNCEMENT LBL-024 (OPAMTISTOMIG, PD-L1/4-1BB BISPECIFIC ANTIBODY) PHASE II CLINICAL STUDY FOR FIRST-LINE TREATMENT ... | 1 | HKEx | ||
| 21.08. | LEADS BIOLABS-B Vilosyn New Drug Application Accepted | 3 | AASTOCKS | ||
| 21.08. | LEADS BIOLABS-B (09887): VOLUNTARY ANNOUNCEMENT LBL-024 (OPAMTISTOMIG, PD-L1/4-1BB BISPECIFIC ANTIBODY) NEW DRUG APPLICATION ACCEPTED FOR REVIEW BY NMPA | 1 | HKEx | ||
| 20.08. | LEADS BIOLABS CO., LTD.: Leads Biolabs' Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Abstract Published by WCLC: Extended Follow-Up Shows Continued Efficacy Improvement | 1 | GlobeNewswire (USA) | ||
| 20.08. | LEADS BIOLABS-B 'LBL-024' Phase II Study for Non-Small Cell Lung Cancer Achieves 65% Objective Response Rate | 1 | AASTOCKS | ||
| 20.08. | LEADS BIOLABS-B Receives USD10 million Payment as Partner Oblenio Bio Exercises Option for LBL-051 | 1 | AASTOCKS | ||
| 20.08. | LEADS BIOLABS-B (09887): VOLUNTARY ANNOUNCEMENT LBL-024 (OPAMTISTOMIG, PD-L1/4-1BB BISPECIFIC ANTIBODY) PHASE II CLINICAL STUDY ABSTRACT FOR FIRST-LINE ... | 1 | HKEx | ||
| 20.08. | LEADS BIOLABS-B (09887): VOLUNTARY ANNOUNCEMENT OBLENIO EXERCISED OPTION TO RETAIN ITS LICENSE FOR LBL-051 | 1 | HKEx | ||
| 19.08. | LEADS BIOLABS-B (09887): DATE OF BOARD MEETING | - | HKEx | ||
| 06.08. | LEADS BIOLABS CO., LTD.: Leads Biolabs' Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Advances to Expansion Phase in First-Line Hepatocellular Carcinoma Following Positive Efficacy Signals | 147 | GlobeNewswire (Europe) | NANJING, China, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company," Stock Code: 9887.HK) today announced that its Phase II clinical study evaluating... ► Artikel lesen | |
| 06.08. | LEADS BIOLABS-B (09887): VOLUNTARY ANNOUNCEMENT PHASE II STUDY OF LBL-024 (OPAMTISTOMIG, PD-L1/4-1BB BISPECIFIC ANTIBODY) FOR HEPATOCELLULAR CARCINOMA ... | 1 | HKEx | ||
| 04.08. | LEADS BIOLABS CO., LTD.: Leads Biolabs Announces Partner Oblenio Bio Doses First Patients in Phase 1a Trial of LBL-051 for Refractory Autoimmune Diseases | 297 | GlobeNewswire (Europe) | NANJING, China, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company," Stock Code: 9887.HK) today announced that its partner company with Aditum Bio,... ► Artikel lesen | |
| 04.08. | LEADS BIOLABS-B (09887): VOLUNTARY ANNOUNCEMENT PARTNER OBLENIO DOSES FIRST PATIENTS IN PHASE IA TRIAL OF LBL-051 FOR REFRACTORY AUTOIMMUNE DISEASES AND ... | - | HKEx |
1 2 3 4 Weiter >>
64 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ERASCA | 16,000 | 0,00 % | FDA Fast Track Puts Erasca's (ERAS) Pancreatic Bet Center Stage | ||
| QIAGEN | 36,615 | -0,01 % | QIAGEN N.V. - 6-K, Report of foreign issuer | ||
| TANGO THERAPEUTICS | 23,510 | -2,12 % | Tango Therapeutics, Inc.: Tango Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights | Company continues to prepare for late-stage clinical advancement of vopimetostat in combination with daraxonrasib for pancreatic cancer following positive Phase 1/2 data Phase 1/2 data from combination... ► Artikel lesen | |
| DYNE THERAPEUTICS | 17,970 | -6,36 % | Aktien New York Ausblick: Dow schwächelt weiter - Nasdaq stabil erwartet | NEW YORK (dpa-AFX) - Die US-Börsen steuern nach dem verlängerten Wochenende am Dienstag auf eine durchwachsene Eröffnung zu. Auf die Stimmung drückten die weiter steigenden Ölpreise, die der Angst... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 16,860 | -3,88 % | Mercks 30-Milliarden-Dollar-Blockbuster bekommt neue Konkurrenz - warum Big Pharma schon die nächste Plattform sucht | ||
| KYMERA THERAPEUTICS | 117,62 | +1,90 % | Kymera Therapeutics auf Citigroup-Gipfel: Offensive bei oralen Immunologie-Medikamenten gewinnt an Fahrt | ||
| RELAY THERAPEUTICS | 18,935 | +1,42 % | Relay Therapeutics: Zovegalisib-Pipeline steht vor entscheidenden Meilensteinen | ||
| BEAM THERAPEUTICS | 24,170 | -3,99 % | Beam Therapeutics Presents Updated Clinical Data from the Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the European Respiratory Society (ERS) Congress 2026 | BEAM-302 Continues to Demonstrate Potential as One-time Treatment for Both Lung and Liver Manifestations of AATD, with AAT Protein Production Under Normal Physiological Control With Up to 18 Months... ► Artikel lesen | |
| COGENT BIOSCIENCES | 33,750 | -1,17 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Submission of New Drug Application (NDA) for Bezuclastinib in Advanced Systemic Mastocytosis (AdvSM) | Submission based on results of APEX pivotal trial which demonstrated bezuclastinib objective response rate (CR+CRh+PR+CI) of 65% per mIWG criteria and 81% ORR per PPR criteria with a well-tolerated... ► Artikel lesen | |
| VERA THERAPEUTICS | 33,490 | -0,86 % | Vera Therapeutics: Erfolgreicher Start für Nierenmedikament TRUTAKNA | ||
| TYRA BIOSCIENCES | 23,260 | +5,68 % | Tyra Biosciences Reports Initial Phase 2 SURF302 Results Supporting the First Potential Oral Innovation in LG IR NMIBC with Dabogratinib | TYRA's mission is to make dabogratinib the clear first-line treatment choice for patients with LG IR NMIBC
Favorable safety and tolerability results support chronic... ► Artikel lesen | |
| ALUMIS | 9,820 | +0,20 % | Alumis-Aktie: No Brainer Club feiert zweistellige Kursgewinne zum Start | Gewohnt gutes Timing: Der No Brainer Club hat auch bei Alumis im richtigen Moment zugeschlagen und blickt bereits nach einem Tag auf zweistellige Kursgewinne. Nach dem massiven Abverkauf infolge enttäuschender... ► Artikel lesen | |
| IMMUNOVANT | 37,840 | -2,35 % | Immunovant, Inc. - 8-K, Current Report | ||
| PRAXIS PRECISION MEDICINES | 339,80 | -1,59 % | Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| TARSUS PHARMACEUTICALS | 81,47 | -1,57 % | Tarsus Pharmaceuticals, Inc: Tarsus Pharmaceuticals Completes Acquisition of Alkeus Pharmaceuticals, Expanding Leadership in Eye Care | Adds gildeuretinol (ALK-001), a differentiated Phase 3 oral investigational medicine designed to target the underlying biology of Stargardt's disease, a potentially blinding disease with no FDA-approved... ► Artikel lesen |
Das Unternehmen NANJING LEADS BIOLABS CO LTD kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 6,800 Euro und damit -1,45 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NANJING LEADS BIOLABS CO LTD finden Sie auf Wallstreet Online.